skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database

Original Research

(2308) Views  (496) Full article downloads

Authors: Antoine Lafuma, John F Salmon, Julien Robert, et al

Published Date March 2011 Volume 2011:5 Pages 361 - 367
DOI: http://dx.doi.org/10.2147/OPTH.S16888

Antoine Lafuma1, John F Salmon2, Julien Robert1, Gilles Berdeaux3
1Cemka, Bourg-la-Reine, France; 2Oxford Eye Hospital, Oxford, UK; 3Conservatoire National des Arts et Métiers, Chaire Economie et Gestion des Services de Santé, Paris, France

Objective: To compare treatment persistence and costs with 3 glaucoma treatment sequences (first-line/second-line): latanoprost/latanoprost–timolol (LLT), bimatoprost/bimatoprost–timolol (BBT), and travoprost/travoprost–timolol (TTT), derived from the UK General Practitioner Research Database (UK-GPRD).
Methods: Patient records referring to ocular hypertension, topical glaucoma treatment, surgery, or laser therapy were extracted. Patients prescribed LLT, BBT, or TTT sequences were selected. Treatment failure was inferred from glaucoma prescription change (adding or removing a topical treatment, surgery, or laser therapy). Treatment durations preceding failure were compared by applying Wilcoxon’s test to survival curves. Adjustment on confounding variables was performed with a Cox model and a propensity score method. Unit costs were estimated from a UK National Health Service perspective.
Results: A total of 1592 patients received LLT, 110 BBT, and 114 TTT. Their mean age was 68 years and the sex ratio almost 1 male:1 female. No significant demographic or comorbidity differences were observed between treatment sequences. Treatment persistence at 36 months was achieved in 60.0% of LLT, 55.5% of BBT, and 70.3% of TTT patients (P = 0.005). Resources consumed and associated monthly costs were significantly less for the TTT group (£17.74) compared with BBT (£21.30) and LLT (£22.37) groups.
Conclusion: Analysis of data obtained from the UK-GPRD suggests that the TTT treatment sequence achieved longer treatment persistence at lower cost than LLT and BBT.

Keywords: glaucoma, travoprost, timolol, latanoprost, bimatoprost, persistency, costs




 

Other articles by Dr Gilles Berdeaux

Comparison of outcomes with multifocal intraocular lenses: a meta-analysis
Cost of cataract surgery after implantation of three intraocular lenses
Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database
Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
Five-year extension of a clinical trial comparing the EX-PRESS glaucoma filtration device and trabeculectomy in primary open-angle glaucoma
Identification of noncompliant glaucoma patients using Bayesian networks and the Eye-Drop Satisfaction Questionnaire
Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: a survey
Spectacle independence and subjective satisfaction of ReSTOR® multifocal intraocular lens after cataract or presbyopia surgery in two European countries


Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
Effect of prior cataract surgery on the long-term outcome of selective laser trabeculoplasty
Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination